dihexa commercial injectable formulation Capsules Dihexa Peptide Therapy: Brain &

Sildenafil (Viagra) Summary of Product Characteristics

In some embodiments, the otic pharmaceutical formulation comprises between about 65% to about 99.99% by weight of the triglycerides

AP-1 analysis NHDF were lysed in 20 mM TRIS-HCl, pH 7.6, containing 150 mM NaCl plus 1% Triton X-100, lysis buffer and 2 protease inhibitors, protease cocktail I (Calbiochem), and Complete protease inhibitor (Roche), PhosSTOP phosphatase inhibitor (Roche), 4 mM MgCl 2 and benzonase (Sigma-Aldrich) at 1:1000 dilution in sample buffer (35 ul per well of 24-well plate)

2 mL gives ~2,500 mcg/mL (advanced)

The peptide was administered intravenously in varying intervals over seven days

Zito PM, Raggio BS